image
Technology - Hardware, Equipment & Parts - NASDAQ - US
$ 102.435
-2.07 %
$ 556 M
Market Cap
-2.25
P/E
1. INTRINSIC VALUE

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research.[ Read More ]

The intrinsic value of one MLAB stock under the base case scenario is HIDDEN Compared to the current market price of 102 USD, Mesa Laboratories, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MLAB

image
FINANCIALS
216 M REVENUE
-1.32%
-272 M OPERATING INCOME
-791.93%
-254 M NET INCOME
-27338.28%
44.1 M OPERATING CASH FLOW
57.71%
-81.3 M INVESTING CASH FLOW
-756.39%
32.8 M FINANCING CASH FLOW
198.52%
57.8 M REVENUE
-0.58%
3.51 M OPERATING INCOME
-37.13%
3.43 M NET INCOME
1.18%
5.27 M OPERATING CASH FLOW
-49.48%
-1.79 M INVESTING CASH FLOW
-100.67%
-8.61 M FINANCING CASH FLOW
5.48%
Balance Sheet Decomposition Mesa Laboratories, Inc.
image
Current Assets 109 M
Cash & Short-Term Investments 28.2 M
Receivables 39.1 M
Other Current Assets 42.1 M
Non-Current Assets 337 M
Long-Term Investments 0
PP&E 41.4 M
Other Non-Current Assets 296 M
Current Liabilities 44.3 M
Accounts Payable 6.04 M
Short-Term Debt 2.99 M
Other Current Liabilities 35.3 M
Non-Current Liabilities 257 M
Long-Term Debt 228 M
Other Non-Current Liabilities 28.8 M
EFFICIENCY
Earnings Waterfall Mesa Laboratories, Inc.
image
Revenue 216 M
Cost Of Revenue 82.9 M
Gross Profit 133 M
Operating Expenses 407 M
Operating Income -272 M
Other Expenses -17.8 M
Net Income -254 M
RATIOS
61.64% GROSS MARGIN
61.64%
-125.85% OPERATING MARGIN
-125.85%
-117.60% NET MARGIN
-117.60%
-174.87% ROE
-174.87%
-56.90% ROA
-56.90%
-68.36% ROIC
-68.36%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Mesa Laboratories, Inc.
image
Net Income -254 M
Depreciation & Amortization 31.6 M
Capital Expenditures -2.57 M
Stock-Based Compensation 11.9 M
Change in Working Capital 5.97 M
Others 276 M
Free Cash Flow 41.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Mesa Laboratories, Inc.
image
Wall Street analysts predict an average 1-year price target for MLAB of $120 , with forecasts ranging from a low of $120 to a high of $120 .
MLAB Lowest Price Target Wall Street Target
120 USD 17.15%
MLAB Average Price Target Wall Street Target
120 USD 17.15%
MLAB Highest Price Target Wall Street Target
120 USD 17.15%
4. DIVIDEND ANALYSIS
0.12% DIVIDEND YIELD
0.16 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Mesa Laboratories, Inc.
image
Sold
0-3 MONTHS
759 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
169 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Oct 28, 2024
Sell 286 K USD
Owens Gary M
President and CEO
- 2518
113.616 USD
2 weeks ago
Oct 29, 2024
Sell 286 K USD
Owens Gary M
President and CEO
- 2551
111.976 USD
2 months ago
Sep 13, 2024
Sell 187 K USD
Archbold Brian David
SVP Operations
- 1499
125 USD
11 months ago
Dec 15, 2023
Sell 169 K USD
Archbold Brian David
SVP Operations
- 1500
112.36 USD
1 year ago
Sep 14, 2023
Sell 369 K USD
Schmieder John Bradley
Director
- 3000
123.05 USD
1 year ago
Sep 15, 2023
Sell 124 K USD
Schmieder John Bradley
Director
- 1000
123.74 USD
1 year ago
Sep 13, 2023
Sell 370 K USD
Schmieder John Bradley
Director
- 3000
123.3217 USD
1 year ago
Sep 01, 2023
Sell 286 K USD
Owens Gary M
President and CEO
- 2000
142.82 USD
1 year ago
Mar 24, 2023
Sell 188 K USD
Sakys John
CFO
- 1128
167.01 USD
1 year ago
Mar 22, 2023
Sell 429 K USD
Sakys John
CFO
- 2500
171.62 USD
1 year ago
Mar 15, 2023
Sell 166 K USD
Sakys John
CFO
- 1000
165.71 USD
1 year ago
Mar 09, 2023
Sell 68 K USD
Sakys John
CFO
- 400
169.97 USD
1 year ago
Feb 09, 2023
Sell 184 K USD
Sakys John
CFO
- 1000
184.27 USD
1 year ago
Jan 23, 2023
Sell 441 K USD
Sakys John
CFO
- 2100
210.19 USD
1 year ago
Jan 13, 2023
Sell 301 K USD
Schmieder John Bradley
Director
- 1571
191.31 USD
1 year ago
Jan 13, 2023
Sell 301 K USD
Schmieder John Bradley
Director
- 1571
191.31 USD
1 year ago
Dec 08, 2022
Sell 40.2 K USD
Hall Shannon
Director
- 230
174.975 USD
2 years ago
Nov 11, 2022
Sell 439 K USD
Schmieder John Bradley
Director
- 2500
175.45 USD
2 years ago
Aug 18, 2022
Sell 724 K USD
GUILLEMIN EVAN
director:
- 3692
196.12 USD
2 years ago
Aug 15, 2022
Sell 126 K USD
Sakys John
CFO
- 628
200.54 USD
2 years ago
Aug 16, 2022
Sell 275 K USD
Sakys John
CFO
- 1372
200.58 USD
2 years ago
Aug 15, 2022
Sell 126 K USD
Sakys John
CFO
- 628
200.54 USD
2 years ago
Aug 15, 2022
Sell 275 K USD
Sakys John
CFO
- 1372
200.58 USD
2 years ago
Aug 09, 2022
Bought 100 K USD
Tripeny R Tony
director:
+ 500
200 USD
2 years ago
Jun 17, 2022
Sell 331 K USD
Owens Gary M
President and CEO
- 1756
188.224 USD
2 years ago
Jun 17, 2022
Sell 73.8 K USD
Archbold Brian David
SVP Operations
- 392
188.224 USD
2 years ago
Jun 17, 2022
Sell 104 K USD
DINOIA GREGORY
SVP Commercial
- 555
188.224 USD
2 years ago
Jun 17, 2022
Sell 136 K USD
Sakys John
CFO
- 722
188.224 USD
2 years ago
Jun 07, 2022
Sell 1.08 M USD
Sullivan John James
Director
- 5192
207.76 USD
2 years ago
Jun 07, 2022
Sell 1.08 M USD
Sullivan John James
director:
- 5192
207.76 USD
2 years ago
Apr 20, 2022
Sell 18 K USD
Sakys John
CFO
- 72
250.44 USD
2 years ago
Mar 23, 2022
Sell 234 K USD
Sakys John
CFO
- 930
251.29 USD
2 years ago
Mar 24, 2022
Sell 168 K USD
Sakys John
CFO
- 670
251.15 USD
2 years ago
Feb 15, 2022
Sell 1.35 M USD
Sullivan John James
Director
- 5192
259.42 USD
2 years ago
Jan 03, 2022
Sell 328 K USD
Schmieder John Bradley
Director
- 1000
327.77 USD
2 years ago
Dec 14, 2021
Sell 539 K USD
Archbold Brian David
SVP Operations
- 1659
325.02 USD
2 years ago
Dec 10, 2021
Sell 571 K USD
Sakys John
CFO
- 1758
324.74 USD
2 years ago
Dec 02, 2021
Sell 721 K USD
GUILLEMIN EVAN
Director
- 2320
310.61 USD
3 years ago
Nov 15, 2021
Sell 1.6 M USD
Sullivan John James
Director
- 5192
308.02 USD
3 years ago
Nov 11, 2021
Sell 317 K USD
Sakys John
CFO
- 1000
317.12 USD
3 years ago
Nov 08, 2021
Sell 5.83 K USD
KELLY DAVID M
Director
- 18
324.07 USD
3 years ago
Nov 08, 2021
Sell 90.6 K USD
DINOIA GREGORY
SVP Commercial
- 280
323.72 USD
3 years ago
Oct 20, 2021
Sell 620 K USD
Sakys John
CFO
- 2000
309.86 USD
3 years ago
Oct 01, 2021
Sell 381 K USD
Sullivan John James
Director
- 1250
304.48 USD
3 years ago
Sep 10, 2021
Sell 378 K USD
Sakys John
CFO
- 1400
270.21 USD
3 years ago
Sep 01, 2021
Sell 335 K USD
Sullivan John James
Director
- 1250
268.22 USD
3 years ago
Aug 31, 2021
Sell 161 K USD
KELLY DAVID M
Director
- 603
267.29 USD
3 years ago
Aug 16, 2021
Sell 1.41 M USD
Sullivan John James
Director
- 5192
272.16 USD
3 years ago
Aug 12, 2021
Sell 275 K USD
Sakys John
CFO
- 1000
275.16 USD
3 years ago
Aug 11, 2021
Sell 222 K USD
Schmieder John Bradley
Director
- 800
278.06 USD
3 years ago
Aug 09, 2021
Sell 179 K USD
Archbold Brian David
SVP Continuous Improvement
- 639
280.03 USD
3 years ago
Aug 02, 2021
Sell 363 K USD
Sullivan John James
Director
- 1250
290.47 USD
3 years ago
Jul 16, 2021
Sell 203 K USD
GUILLEMIN EVAN
Director
- 720
282.18 USD
3 years ago
Jul 12, 2021
Sell 279 K USD
Sakys John
CFO
- 1000
278.77 USD
3 years ago
Jul 01, 2021
Sell 267 K USD
Sakys John
CFO
- 1000
267.04 USD
3 years ago
Jul 01, 2021
Sell 334 K USD
Sullivan John James
Director
- 1250
267.44 USD
3 years ago
Jun 17, 2021
Sell 103 K USD
Archbold Brian David
SVP Continuous Improvement
- 400
256.56 USD
3 years ago
Jun 16, 2021
Sell 132 K USD
Schmieder John Bradley
Director
- 505
262.27 USD
3 years ago
Jun 16, 2021
Sell 542 K USD
Sakys John
CFO
- 2119
255.67 USD
3 years ago
Jun 16, 2021
Sell 1.67 M USD
Owens Gary M
President and CEO
- 6545
255.67 USD
3 years ago
Jun 16, 2021
Sell 310 K USD
DINOIA GREGORY
SVP Commericial
- 1211
255.67 USD
3 years ago
Jun 16, 2021
Sell 235 K USD
Archbold Brian David
SVP Continuous Improvement
- 921
255.67 USD
3 years ago
Jun 16, 2021
Sell 108 K USD
Archbold Brian David
SVP Continuous Improvement
- 415
260.14 USD
3 years ago
Jun 16, 2021
Sell 185 K USD
GUILLEMIN EVAN
Director
- 720
256.36 USD
3 years ago
Jun 08, 2021
Sell 1.34 M USD
Sullivan John James
Director
- 5192
258.19 USD
3 years ago
Jun 07, 2021
Sell 356 K USD
Owens Gary M
President and CEO
- 1350
264 USD
3 years ago
Jun 04, 2021
Sell 221 K USD
KELLY DAVID M
Director
- 851
260.28 USD
3 years ago
Jun 04, 2021
Sell 141 K USD
DINOIA GREGORY
SVP Commercial
- 540
260.27 USD
3 years ago
Jun 01, 2021
Sell 557 K USD
Sullivan John James
Director
- 2215
251.46 USD
3 years ago
May 17, 2021
Sell 176 K USD
GUILLEMIN EVAN
Director
- 720
244.25 USD
3 years ago
May 05, 2021
Sell 25.1 K USD
Sullivan John James
Director
- 100
250.59 USD
3 years ago
May 06, 2021
Sell 50 K USD
Sullivan John James
Director
- 200
250.05 USD
3 years ago
May 04, 2021
Sell 184 K USD
Sullivan John James
Director
- 735
250.14 USD
3 years ago
Apr 16, 2021
Sell 183 K USD
GUILLEMIN EVAN
Director
- 720
253.77 USD
3 years ago
Apr 05, 2021
Sell 125 K USD
Sullivan John James
Director
- 500
250.76 USD
3 years ago
Apr 05, 2021
Sell 125 K USD
Sullivan John James
Director
- 500
250.76 USD
3 years ago
Mar 16, 2021
Sell 194 K USD
GUILLEMIN EVAN
Director
- 720
269.48 USD
3 years ago
Mar 12, 2021
Sell 660 K USD
Sakys John
CFO
- 2500
263.84 USD
3 years ago
Mar 10, 2021
Sell 60.6 K USD
Archbold Brian David
SVP Continuous Improvement
- 223
271.78 USD
3 years ago
Mar 01, 2021
Sell 342 K USD
Sullivan John James
Director
- 1250
273.94 USD
3 years ago
Feb 23, 2021
Sell 77.5 K USD
DINOIA GREGORY
SVP Commericial
- 280
276.75 USD
3 years ago
Feb 16, 2021
Sell 1.01 M USD
GUILLEMIN EVAN
Director
- 3600
281.52 USD
3 years ago
Feb 10, 2021
Sell 487 K USD
Schmieder John Bradley
Director
- 1750
278.23 USD
3 years ago
Feb 01, 2021
Sell 347 K USD
Sullivan John James
Director
- 1250
277.67 USD
3 years ago
Jan 12, 2021
Sell 136 K USD
Schmieder John Bradley
Director
- 477
285.23 USD
3 years ago
Jan 06, 2021
Sell 4.64 K USD
Sakys John
CFO
- 16
290 USD
3 years ago
Jan 04, 2021
Sell 351 K USD
Sullivan John James
Director
- 1250
280.82 USD
3 years ago
Dec 11, 2020
Sell 70.8 K USD
KELLY DAVID M
Director
- 250
283.18 USD
3 years ago
Dec 01, 2020
Sell 344 K USD
Sullivan John James
Director
- 1250
275.22 USD
4 years ago
Nov 17, 2020
Sell 285 K USD
Sakys John
CFO
- 984
290 USD
4 years ago
Nov 16, 2020
Sell 199 K USD
KELLY DAVID M
Director
- 704
283.31 USD
4 years ago
Nov 13, 2020
Sell 562 K USD
GUILLEMIN EVAN
Director
- 2050
274.3 USD
4 years ago
Nov 12, 2020
Sell 260 K USD
GUILLEMIN EVAN
Director
- 950
273.77 USD
4 years ago
Nov 11, 2020
Sell 340 K USD
Sullivan John James
Director
- 1250
272.36 USD
4 years ago
Nov 09, 2020
Sell 145 K USD
Archbold Brian David
SVP Continuous Improvement
- 533
272.11 USD
4 years ago
Oct 08, 2020
Sell 261 K USD
Sakys John
CFO
- 942
276.9 USD
4 years ago
Oct 07, 2020
Sell 186 K USD
Owens Gary M
President and CEO
- 677
275 USD
4 years ago
Oct 08, 2020
Sell 89.4 K USD
Owens Gary M
President and CEO
- 323
276.91 USD
4 years ago
Oct 06, 2020
Sell 265 K USD
Owens Gary M
President and CEO
- 1000
265 USD
4 years ago
Oct 02, 2020
Sell 70.2 K USD
DINOIA GREGORY
SVP Commercial
- 270
260 USD
4 years ago
Oct 02, 2020
Sell 16.1 K USD
DINOIA GREGORY
SVP Commercial
- 62
260 USD
4 years ago
Sep 16, 2020
Sell 24.9 K USD
Owens Gary M
President and CEO
- 100
249.32 USD
4 years ago
Sep 04, 2020
Sell 68.2 K USD
DINOIA GREGORY
SVP Commerical
- 280
243.55 USD
4 years ago
Sep 01, 2020
Sell 74.5 K USD
Sakys John
CFO
- 298
250 USD
4 years ago
Sep 02, 2020
Sell 176 K USD
Sakys John
CFO
- 702
251.42 USD
4 years ago
Aug 28, 2020
Sell 43.9 K USD
KELLY DAVID M
Director
- 180
244 USD
4 years ago
Aug 31, 2020
Sell 147 K USD
KELLY DAVID M
Director
- 600
245 USD
4 years ago
Aug 17, 2020
Sell 198 K USD
KELLY DAVID M
Director
- 800
247.72 USD
4 years ago
Aug 17, 2020
Sell 205 K USD
DINOIA GREGORY
SVP Commercial
- 835
245.7 USD
4 years ago
Aug 14, 2020
Sell 244 K USD
Sakys John
CFO
- 1000
244 USD
4 years ago
Aug 12, 2020
Sell 352 K USD
Schmieder John Bradley
Director
- 1429
246.29 USD
4 years ago
Aug 10, 2020
Sell 105 K USD
Archbold Brian David
SVP Continuous Improvement
- 420
250 USD
4 years ago
Aug 10, 2020
Sell 9.5 K USD
Archbold Brian David
SVP Continuous Improvement
- 38
250 USD
4 years ago
Aug 10, 2020
Sell 236 K USD
KELLY DAVID M
Director
- 942
250 USD
7. News
Mesa Labs (MLAB) Lags Q2 Earnings and Revenue Estimates Mesa Labs (MLAB) came out with quarterly earnings of $2.45 per share, missing the Zacks Consensus Estimate of $2.48 per share. This compares to earnings of $1.91 per share a year ago. zacks.com - 1 week ago
Mesa Labs Announces Second Quarter Results LAKEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter (“2Q25”) ended September 30, 2024 (amounts in thousands). globenewswire.com - 1 week ago
MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. globenewswire.com - 1 month ago
Surging Earnings Estimates Signal Upside for Mesa Labs (MLAB) Stock Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. zacks.com - 2 months ago
Mesa Labs (MLAB) Moves to Strong Buy: Rationale Behind the Upgrade Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com - 2 months ago
New Strong Buy Stocks for August 26th QFIN, GHM, CRNC, SUPV and MLAB have been added to the Zacks Rank #1 (Strong Buy) List on August 26, 2024. zacks.com - 2 months ago
Mesa Labs Announces First Quarter Results LAKEWOOD, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q25”) ended June 30, 2024 (amounts in thousands). globenewswire.com - 3 months ago
MESA LABS DECLARES QUARTERLY DIVIDEND Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024. globenewswire.com - 4 months ago
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q24”) and fiscal year (“FY24”) ended March 31, 2024 (amounts in thousands). globenewswire.com - 5 months ago
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as previously communicated. The earnings announcement has been delayed as we work to finalize our year end audit which is focused on finalizing the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions and the purchase accounting associated with the acquisition of GKE. globenewswire.com - 5 months ago
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results to May 31, 2024 LAKEWOOD, Colo., May 22, 2024 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 31, 2024. Mesa's Form 10-K will be filed the same day. The earnings announcement has been delayed as we finalize the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions. globenewswire.com - 5 months ago
MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES Lakewood, Colo., April 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced the closing of its Amended and Restated Credit Agreement (the “Credit Agreement”), which provides up to $200 million of senior secured debt through a syndicate of banks led by JPMORGAN CHASE BANK, N.A. The Credit Agreement includes a $75 million senior secured term loan facility (the “Term Loan”) and a $125 million senior secured revolving credit facility (the “Revolver”), both of which mature in April 2029. The Credit Agreement includes a ten-year amortization schedule and no springing maturity relating to the Company's 1.375% Convertible Senior Notes due August 2025 (the “2025 Notes”). Both the Term Loan and the Revolver bear interest at a rate of SOFR plus an applicable margin ranging from 1.5% to 3.5%, depending on the Company's total Net Leverage Ratio. Proceeds from the Term Loan and Revolver will be used to pay down the Company's 2025 Notes and for normal operating expenditures. The Credit Agreement also allows funds to be used for permitted acquisitions. globenewswire.com - 7 months ago
8. Profile Summary

Mesa Laboratories, Inc. MLAB

image
COUNTRY US
INDUSTRY Hardware, Equipment & Parts
MARKET CAP $ 556 M
Dividend Yield 0.12%
Description Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Contact 12100 West Sixth Avenue, Lakewood, CO, 80228 https://www.mesalabs.com
IPO Date Feb. 29, 1984
Employees 736
Officers Mr. Gary M. Owens Chief Executive Officer, President & Director Mr. Brian David Archbold Senior Vice President of Continuous Improvement